Asian Market Insights: 3 Penny Stocks With Market Caps Larger Than US$90M

As the Asian markets navigate a landscape marked by global volatility and shifting investor sentiment, opportunities continue to emerge for those looking beyond traditional large-cap investments. Penny stocks, often associated with smaller or newer companies, remain an intriguing area of focus due to their potential for growth and affordability. While the term may seem outdated, these stocks can offer significant value when backed by strong financials, as demonstrated by the three noteworthy examples we'll explore in this article.

Top 10 Penny Stocks In Asia

Name	Share Price	Market Cap	Rewards & Risks
Lever Style (SEHK:1346)	HK$1.38	HK$853.56M	✅ 4 ⚠️ 1 View Analysis >
Asia Medical and Agricultural Laboratory and Research Center (SET:AMARC)	THB2.64	THB1.11B	✅ 3 ⚠️ 3 View Analysis >
Plan B Media (SET:PLANB)	THB3.68	THB16.93B	✅ 5 ⚠️ 2 View Analysis >
TK Group (Holdings) (SEHK:2283)	HK$2.44	HK$2.02B	✅ 4 ⚠️ 1 View Analysis >
Panjawattana Plastic (SET:PJW)	THB2.02	THB1.17B	✅ 4 ⚠️ 2 View Analysis >
Atlantic Navigation Holdings (Singapore) (Catalist:5UL)	SGD0.128	SGD67.01M	✅ 2 ⚠️ 3 View Analysis >
Halcyon Technology (SET:HTECH)	THB3.26	THB978M	✅ 2 ⚠️ 3 View Analysis >
Yangzijiang Shipbuilding (Holdings) (SGX:BS6)	SGD3.16	SGD12.44B	✅ 5 ⚠️ 1 View Analysis >
Livestock Improvement (NZSE:LIC)	NZ$1.01	NZ$143.77M	✅ 2 ⚠️ 3 View Analysis >
Scott Technology (NZSE:SCT)	NZ$2.85	NZ$240.51M	✅ 4 ⚠️ 0 View Analysis >

Click here to see the full list of 952 stocks from our Asian Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Majestic Dragon AeroTech Holdings (SEHK:918)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Majestic Dragon AeroTech Holdings Limited is an investment holding company involved in the wholesale of timepieces, accessories, garments, and sportswear across Africa, Hong Kong, Mainland China, and Taiwan with a market cap of approximately HK$735.29 million.

Operations: Majestic Dragon AeroTech Holdings generates revenue from its wholesale business at HK$124.85 million and its unmanned aerial vehicles segment at HK$50.62 million, with additional income from property investment amounting to HK$0.95 million.

Market Cap: HK$735.29M

Majestic Dragon AeroTech Holdings has shown a turnaround in profitability, reporting net income of HK$6.06 million for the half year ended September 2025, compared to a loss the previous year. The company's debt is well covered by operating cash flow and it holds more cash than its total debt, indicating strong financial health. However, its weekly volatility remains higher than most Hong Kong stocks. A recent non-binding letter of intent from Beijing Qichen Investment Management to acquire a significant stake could impact future dynamics. Despite these positives, the board's average tenure suggests limited experience which might affect strategic decisions.

• Click here and access our complete financial health analysis report to understand the dynamics of Majestic Dragon AeroTech Holdings.
• Explore historical data to track Majestic Dragon AeroTech Holdings' performance over time in our past results report.

Zhongzhu Healthcare HoldingLtd (SHSE:600568)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Zhongzhu Healthcare Holding Co., Ltd is involved in the research, development, production, and sale of drugs in China with a market cap of CN¥5.29 billion.

Operations: The company's revenue is generated entirely from China, amounting to CN¥570.62 million.

Market Cap: CN¥5.29B

Zhongzhu Healthcare Holding Ltd. is currently unprofitable, with a negative return on equity of -32.97%. Despite this, the company has no debt and maintains a strong cash position, with short-term assets of CN¥1.2 billion covering both short- and long-term liabilities comfortably. The management team and board are relatively new, with average tenures under two years, which may impact strategic stability. Recently, Gongqingcheng Meihua Tenglong Qifei Investment Partnership acquired a 10.38% stake for approximately CN¥400 million at CN¥1.95 per share, potentially influencing future governance and financial strategies as confirmed by the Shanghai Stock Exchange compliance confirmation.

• Click to explore a detailed breakdown of our findings in Zhongzhu Healthcare HoldingLtd's financial health report.
• Gain insights into Zhongzhu Healthcare HoldingLtd's past trends and performance with our report on the company's historical track record.

Shenzhen Glory MedicalLtd (SZSE:002551)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Shenzhen Glory Medical Co., Ltd. provides hospital construction and medical system integrated solutions both in China and internationally, with a market cap of CN¥3.26 billion.

Operations: Shenzhen Glory Medical Co., Ltd. has not reported specific revenue segments.

Market Cap: CN¥3.26B

Shenzhen Glory Medical Co., Ltd. is currently unprofitable, with a negative return on equity of -1%. Despite this, the company maintains a strong financial position; its short-term assets of CN¥1.6 billion exceed both short- and long-term liabilities, and it has more cash than total debt. The debt-to-equity ratio has significantly decreased over the past five years from 14.6% to 2.9%, indicating improved financial health. Although losses have increased by 35.1% annually over five years, operating cash flow covers 55.3% of its debt, suggesting robust liquidity management despite ongoing profitability challenges.

• Unlock comprehensive insights into our analysis of Shenzhen Glory MedicalLtd stock in this financial health report.
• Review our historical performance report to gain insights into Shenzhen Glory MedicalLtd's track record.

Key Takeaways

• Reveal the 952 hidden gems among our Asian Penny Stocks screener with a single click here.
• Looking For Alternative Opportunities? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com